NUVB Earnings & Financial Statements
Nuvation Bio Inc.
$4.95
-$0.19(-3.70%)
36
Overall
50
Value
36
Tech
23
Quality
Market Cap
$1.74B
Volume
9.96M
52W Range
$3.36 - $9.75
Target Price
$13.30
NUVB earnings and financial statements: Nuvation Bio Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NUVB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $62.90M | $7.87M | - | - | - |
| Cost of revenue | $9.30M | $7.08M | - | - | - |
| Operating income | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M |
| EBITDA | -$188.54M | -$567.45M | -$75.58M | -$119.53M | -$93.13M |
| Net income | -$204.63M | -$567.94M | -$75.80M | -$104.20M | -$86.85M |
| EPS (diluted) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $594.82M | $540.63M | $621.48M | $672.14M | $776.15M |
| Total liabilities | $289.11M | $76.84M | $16.36M | $17.07M | $30.15M |
| Shareholders’ equity | $305.72M | $463.79M | $605.12M | $655.08M | $746.00M |
| Cash and equivalents | $164.09M | $35.72M | $42.65M | $101.10M | $132.42M |
| Long-term debt | $49.75M | $969.0K | $2.04M | $3.05M | $2.19M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$173.43M | -$130.41M | -$68.00M | -$96.11M | -$68.19M |
| Capital expenditure | -$8.35M | -$162.0K | -$69.0K | -$370.0K | -$282.0K |
| Free cash flow | -$181.78M | -$130.57M | -$68.07M | -$96.48M | -$68.47M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NUVB | $4.95 | -3.7% | 9.96M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |